ARTICLE | Clinical News
ALKS 8700: Phase I data
February 16, 2015 8:00 AM UTC
Top-line data from a double-blind, placebo- and active-controlled Phase I trial in 104 healthy volunteers showed that multiple formulations of 49-980 mg oral ALKS 8700 were generally well tolerated wi...